Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D 1/D 2/D 3 receptors vs D 2/D 3 receptors only: Parallel observations from co-transfected human and native cerebral receptors

Neuropharmacology

Volumn 60, Issue 2-3, 2011, Pages 439-445

  Aloisi, Gabriella ^a   Silvano, Elena ^a   Rossi, Mario ^a,c   Millan, Mark J ^b   Maggio, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Adenylyl cyclase; Dopamine receptor; Gambling; Heterodimer; Heteromerization; Supersensitivity

Indexed keywords

ADENYLATE CYCLASE; ANTIPARKINSON AGENT; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PRAMIPEXOLE; QUINPIROLE; ROPINIROLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN LEVEL; CONTROLLED STUDY; DRUG EXPOSURE; DRUG RECEPTOR BINDING; DRUG SENSITIZATION; GENETIC TRANSFECTION; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ADENYLATE CYCLASE; ANIMALS; ANTIPARKINSON AGENTS; CEREBRAL CORTEX; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE AGONISTS; ENZYME INDUCTION; HUMANS; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TRANSFECTION;

EID: 78650820096     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.10.018     Document Type: Article

References (50)

1. T. Avidor-Reiss, I. Nevo, D. Saya, M. Bayewitch, and Z. Vogel Opiate-induced adenylyl cyclase superactivation is isozyme-specific J. Biol. Chem. 272 1997 5040 5047
2. 1-dopamine receptors linked to adenylyl cyclase activity in cultured NS20Y neuroblastoma cells Mol. Pharmacol. 38 1990 531 541
3. J.L. Benovic, M. Bouvier, M.G. Caron, and R.J. Lefkowitz Regulation of AC-coupled β-adrenergic receptors Annu. Rev. Cell. Biol. 4 1988 405 428
4. J.M. Bostwick, K.A. Hecksel, S.R. Stevens, J.H. Bower, and J.E. Ahlskog Frequency of new-onset pathological compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease Mayo Clin. Proc. 84 2009 310 316
5. D.E. Clapham, and E.J. Neer G protein beta gamma subunits Annu. Rev. Pharmacol. Toxicol. 37 1997 167 203
6. M.L. Dodd, K.J. Klos, J.H. Bower, Y.E. Geda, K.A. Josephs, and J.E. Ahlskog Pathological gambling caused by drugs used to treat Parkinson disease Arch. Neurol. 62 2005 1377 1381
7. E.D. Driver-Dunckley, B.N. Noble, J.G. Hentz, V.G. Evidente, J.N. Caviness, J. Parish, L. Krahn, and C.H. Adler Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome Clin. Neuropharmacol. 30 2007 249 255
8. S. Ferré, A.S. Woods, G. Navarro, M. Aymerich, C. Lluís, and R. Franco Calcium-mediated modulation of the quaternary structure and function of adenosine A2A-dopamine D2 receptor heteromers Curr. Opin. Pharmacol. 10 2010 67 72
9. C. Fiorentini, C. Busi, E. Gorruso, C. Gotti, P. Spano, and C. Missale Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization Mol. Pharmacol. 74 2008 59 69
10. C. Fiorentini, C. Busi, P. Spano, and C. Missale Dimerization of dopamine D1 and D3 receptors in the regulation of striatal function Curr. Opin. Pharmacol. 10 2010 87 92
11. K. Fuxe, D. Marcellino, G. Leo, and L.F. Agnati Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis Curr. Opin. Pharmacol. 10 2010 14 22
12. T.K. Harden Agonist-induced desensitization of the beta-adrenergic receptor-linked to adenylate cyclase Pharmacol. Rev. 35 1983 5 32
13. A. Hasbi, B.F. O'Dowd, and S.R. George Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms Curr. Opin. Pharmacol. 10 2010 93 99
14. C.A. Heidbreder Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence CNS Neurol. Disord. Drug. Targets 7 2008 410 421
15. 3 receptors in drug addiction: a review of pharmacological evidence Brain Res. Brain Res. Rev. 49 2005 77 105
16. D.L. Jones, J. Petty, D.C. Hoyle, A. Hayes, S.G. Oliver, I. Riba-Garcia, S.J. Gaskell, and L. Stateva Genome-wide analysis of the effects of heat shock on a Saccharomyces cerevisiae mutant with a constitutively activated cAMP-dependent pathway Comp. Funct. Genomics 5 2005 419 431
17. K.J. Klos, J.H. Bower, K.A. Josephs, J.Y. Matsumoto, and J.E. Ahlskog Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy Parkinsonism Relat. Disord. 11 2005 381 386
18. T. Kvernmo, J. Houben, and I. Sylte Receptor-binding and pharmacokinetic properties of dopaminergic agonists Curr. Top. Med. Chem. 8 2008 1049 1067
19. M. Lader Antiparkinsonian medication and pathological gambling CNS Drugs 22 2008 407 416
20. J.R. Lane, B. Powney, A. Wise, S. Rees, and G. Milligan G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors J. Pharmacol. Exp. Ther. 325 2008 319 330
21. R.J. Lefkowitz Seven transmembrane receptors: something old, something new Acta Physiol. (Oxf.) 190 2007 9 19
22. R.J. Lefkowitz, J.M. Stadel, and M.G. Caron Adenylate cyclase-coupled beta-adrenergic receptors: structure and mechanisms of activation and desensitization Annu. Rev. Biochem. 52 1983 159 186
23. M.M. Lewis, V.J. Watts, C.P. Lawler, D.E. Nichols, and R.B. Mailman Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and runctional potency J. Pharmacol. Exp. Ther. 286 1998 345 353
24. R. Maggio, and M.J. Millan Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance Curr. Opin. Pharmacol. 10 2010 100 107
25. D. Marcellino, S. Ferré, V. Casadó, A. Cortés, B. Le Foll, C. Mazzola, F. Drago, O. Saur, H. Stark, A. Soriano, C. Barnes, S.R. Goldberg, C. Lluis, K. Fuxe, and R. Franco Identification of dopamine D1-D3 receptor heteromers indications for a role of synergistic D1-D3 receptor interactions in the striatum J. Biol. Chem. 38 2008 26016 26025
26. A. McKeon, K.A. Josephs, K.J. Klos, K. Hecksel, J.H. Bower, J.M. Bostwick, and J.E. Ahlskog Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy Parkinsonism Relat. Disord. 13 2007 516 519
27. M.J. Millan From the cell to the clinic: A comparative review of the partial D(2)/D(3) receptor agonist and alpha(2)-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease Pharmacol. Ther. 128 2010 239 273
28. 2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole J. Pharmacol. Exp. Ther. 309 2004 903 920 (Pubitemid 38669677)
29. M.J. Millan, A. Gobert, A. Newman-Tancredi, F. Lejeune, D. Cussac, J.M. Rivet, V. Audinot, T. Dubuffet, and G. Lavielle S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626 J. Pharmacol. Exp. Ther. 293 2000 1048 1062
30. M.J. Millan, L. Maiofiss, D. Cussac, V. Audinot, J.A. Boutin, and A. Newman-Tancredi Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J. Pharmacol. Exp. Ther. 303 2002 791 804
31. C. Missale, S.R. Nash, S.W. Robinson, M. Jaber, and M.G. Caron Dopamine receptors: from structure to function Physiol. Rev. 78 1998 189 225
32. I. Nevo, T. Avidor-Reiss, R. Levy, M. Bayewitch, E. Heldman, and Z. Vogel Regulation of adenylyl cyclase isozymes on acute and chronic activation of inhibitory receptors Mol. Pharmacol. 54 1998 419 426
33. 2-like receptor and alpha1/alpha2-adrenoceptor J. Pharmacol. Exp. Ther. 303 2002 805 814 (Pubitemid 35231257)
34. G.Y.K. Ng, B. Mouillac, S.R. George, M.G. Caron, M. Dennis, M. Bouvier, and B.F. O'Dowd Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor Eur. J. Pharmacol. 267 1994 7 19
35. 1 receptor internalization Proc. Natl. Acad. Sci. U.S.A. 92 1995 10157 10161
36. C.W. Olanow, M.B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease Neurology 72 2009 S1 S136
37. S. Ridray, N. Griffon, V. Mignon, E. Souil, S. Carboni, J. Diaz, J.C. Schwartz, and P. Sokoloff Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions Eur. J. Neurosci. 10 1998 1676 1686
38. P. Riederer, M. Gerlach, T. Muller, and H. Reichmann Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease Parkinsonism Relat. Disorder. 13 2007 466 479
39. 3 dopamine receptor heterodimers exhibit unique functional properties J. Biol. Chem. 276 2001 30308 30314
40. S. Seedat, S. Kesler, D.J. Niehaus, and D.J. Stein Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents Depress. Anxiety 11 2000 185 186
41. S.K. Sharma, W.A. Klee, and M. Nirenberg Dual regulation of adenylate cyclase accounts for narcotic dependence and tolerance Proc. Natl. Acad. Sci. U.S.A. 72 1975 3092 3096
42. M.A. Silverdale, S.L. Nicholson, P. Ravenscroft, A.R. Crossman, M.J. Millan, and J.M. Brotchie Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate Exp. Neurol. 188 2004 128 138
43. P. Sokoloff, M. Andrieux, R. Besanon, C. Pilon, M.P. Martres, B. Giros, and J.C. Schwartz Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor Eur. J. Pharmacol. 225 1992 331 337
44. D.J. Surmeier, W.J. Song, and Z. Yan Coordinated expression of dopamine receptors in neostriatal medium spiny neurons J. Neurosci. 16 1996 6579 6591
45. S. Tezelman, J.K. Shaver, R.F. Grossman, W. Liang, A.E. Siperstein, Q.Y. Duh, and O.H. Clark Desensitization of adenylate cyclase in Chinese hamster ovary cells transfected with human thyroid-stimulating hormone receptor Endocrinology 134 1994 1561 1569
46. J.M. Thomas, and B.B. Hoffman Muscarinic cholinergic receptor-induced enhancement of PGE1 stimulated cAMP accumulation in neuroblastoma X glioma cells: prevention by pertussis toxin J. Cyclic Nucleotide Protein Phosphor. Res. 11 1986 317 325
47. R.J. Uitti, and J.E. Ahlskog Comparative review of dopamine receptor agonists in Parkinson's disease CNS Drugs 5 1996 369 388
48. T.A. Vortherms, and V.J. Watts Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation J. Pharmacol. Exp. Ther. 308 2004 221 227
49. V.J. Watts Molecular mechanisms for heterologous sensitization of adenylate cyclase J. Pharmacol. Exp. Ther. 302 2002 1 7
50. V.J. Watts, and K.A. Neve Sensitization of adenylate cyclase by Galpha i/o-coupled receptors Pharmacol. Ther. 106 2005 405 421